Please try another search
For the fiscal year ended 31 December 2021, Medyssey Co Ltd revenues increased 11% to W20.8B. Net income applicable to common stockholders totaled W5.04B vs. loss of W90.1M. Revenues reflect Implant segment increase of 11% to W20.06B, Other segment increase of 7% to W678M, Central/South America segment increase of 26% to W3.61B, United States segment increase of 23% to W3.91B.
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 20804.92 | 18758.83 | 19968.06 | 19571.62 |
Gross Profit | 14982.79 | 12264.55 | 12993.91 | 12330.88 |
Operating Income | 4385.46 | 2379.84 | 1918.92 | 1613.44 |
Net Income | 5111.54 | -94.74 | 1448.2 | 2314.33 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 37817.73 | 34484.95 | 34610.22 | 33370.71 |
Total Liabilities | 12597.75 | 17389.66 | 17755.78 | 18102.57 |
Total Equity | 25219.99 | 17095.29 | 16854.44 | 15268.14 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 12 Months | 12 Months | 12 Months |
Cash From Operating Activities | 5460.63 | 5529.36 | 4306.82 | 1814.79 |
Cash From Investing Activities | -5480.31 | -764.54 | -130.63 | -464.31 |
Cash From Financing Activities | -1907.3 | -828.77 | -2264.25 | 9.69 |
Net Change in Cash | -1884.39 | 3681.08 | 1898.92 | 1341.63 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review